Introduction {#S1}
============

Inflammatory events after ischemic stroke contribute to secondary injury mechanisms that can expand tissue injury and are thus targets of new treatment options ([@B45]). Tumor necrosis factor (TNF) is a multifunctional, proinflammatory cytokine that participates in all phases of ischemic stroke, from development to repair and long-term inflammatory effects (reviewed in [@B29]). It exists both as a transmembrane (tmTNF) and a soluble (solTNF) protein, the latter released via proteolytic cleavage by TNFα converting enzyme (TACE, also called ADAM17) ([@B4]). TNF mediates its effects via TNF receptor 1 (TNFR1, p55TNFR) and 2 (TNFR2, p75TNFR); solTNF primarily mediates acute and chronic inflammation, while tmTNF has been shown to support innate immune function and promote neuronal survival and axonal remyelination, synaptic function, and neurotransmission ([@B68]; [@B2]; [@B6]; [@B3]; [@B9]). In ischemic stroke, TNF plays an important role in infarct development ([@B45]). In support of this, conventional ([@B43]) and conditional myeloid ([@B12]) deletion of TNF resulted in increased infarct volumes in mice subjected to permanent middle cerebral artery occlusion (pMCAO). Interestingly, genetic ablation of solTNF using tmTNF^Δ/Δ^ mice resulted in decreased infarct volumes after pMCAO ([@B53]), suggesting that inhibition of solTNF, but preservation of tmTNF, is required for neuroprotection in ischemic stroke.

Current FDA- and EMA-approved TNF inhibitors are used for treating chronic autoimmune inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis ([@B49]), where they also relieve potential symptoms of depression ([@B84]). The dimeric Fc-fusion protein etanercept targets both tmTNF and solTNF. Being a large (150 kDa) protein, it is not able to cross the blood-brain barrier. When administered perispinally, however, etanercept improved neurological outcome in patients with chronic stroke, traumatic brain injury and Alzheimer's disease ([@B28]; [@B82]; [@B83]; and reviewed in [@B45]). The downside of drugs like etanercept is that inhibition of both solTNF and tmTNF can provoke demyelination and induce neuropathies, infections, sepsis, congestive heart failure and lupus, emphasizing the importance of leaving tmTNF available to preserve adequate function of the innate immune system ([@B70]). XPro1595 is a dominant-negative inhibitor of solTNF ([@B74]). In animal models of multiple sclerosis, XPro1595 promotes axonal preservation and remyelination ([@B6]); in Parkinson's disease XPro1595 reduces neuronal loss ([@B55]; [@B3]); in Alzheimer's disease it decreases beta-amyloid plaques and promotes synaptic function ([@B9]; [@B52]); and in spinal cord injury it decreases lesion volume ([@B63]). We have previously shown that using etanercept and XPro1595 for systemic inhibition of TNF improved functional outcome and affected the inflammatory response after pMCAO in mice, but with no effect on infarct volume ([@B11]). The altered inflammatory response after systemic administration of TNF inhibitors was likely a result of peripheral immunomodulation that decreased the granulocyte infiltration to the ischemic lesion, which was earlier shown to be neuroprotective ([@B73]; [@B11]). Peripheral treatment likely also changed microglial activation ([@B11]). In light of these studies and our earlier studies demonstrating that topical (and not systemic) administration of XPro1595 decreased lesion size following moderate spinal cord injury ([@B63]), we hypothesized that topical and/or intracerebroventricular (i.c.v.) delivery of XPro1595 would reduce lesion size, ameliorate brain inflammation, and improve functional outcome after focal cerebral ischemia in mice.

Materials and Methods {#S2}
=====================

Animals {#S2.SS1}
-------

Adult male C57BL/6 mice (aged 7--8 weeks) were purchased from Taconic Ltd. (Ry, Denmark) and transferred to the Biomedical Laboratory at the University of Southern Denmark, Odense, Denmark. tmTNF^Δ/Δ^ ([@B68]) breeding couples were kindly donated by Dr. Tacchini-Cottier, University of Lausanne, Switzerland and a breeding colony was established at the Biomedical Laboratory at the University of Southern Denmark. Animals were housed under diurnal lighting conditions, and food and water were available *ad libitum.* Mice were allowed to acclimatize for at least 1 week before behavioral testing. All animal experiments were approved by the Danish Animal Inspectorate under the Ministry of Food and Agriculture (J. No. 2013-15-2934-00924).

Permanent Middle Cerebral Artery Occlusion {#S2.SS2}
------------------------------------------

Permanent occlusion of the distal part of the middle cerebral artery was performed by electrocoagulation under Hypnorm-Dormicum anesthesia (fentanyl citrate (0.315 mg/ml, Jansen-Cilag), fluanisone (10 mg/ml, Jansen-Cilag, Birkerød, Denmark), and midazolam (5 mg/ml, Hoffmann-La Roche, Hvidovre, Denmark) as routinely done in our laboratory ([@B46], [@B43]; [@B11], [@B13]). Post-operatively, mice were injected with 0.9% physiological saline subcutaneously (s.c.) and placed in a 28°C heating cabinet for 24 h. Mice with 3 days survival were returned to the conventional animal facility after 24 h. Buprenorphine hydrochloride (0.001 mg/20 g Temgesic, Schering-Plough, Ballerup, Denmark) was administered three times at 8 h intervals starting immediately prior to surgery. Sham mice were subjected to similar surgery but without electrocoagulation of the middle cerebral artery (MCA).

Pharmacological Treatment {#S2.SS3}
-------------------------

Saline, XPro1595 (Xencor Inc., Monrovia, CA, United States), or etanercept (Enbrel, Amgen-Wyeth, Thousand Oak, CA, United States) was administered topically using mini-osmotic pumps (Alzet, 1003D, Durect Corporation, Cupertino, CA, United States) implanted 30 min after pMCAO. XPro1595 and etanercept were diluted in saline for the final concentration. The pumps were placed in such a way that the delivering end of the catheter was on top of the infarct core. The catheter was sutured to the musculature, and the suture and placement of it were secured using Vetbond (3M Animal Care Products, St. Paul, MN, United States). The pumps were set to deliver either saline (0.9% physiological NaCl) with a flow of 1 μl/h, XPro1595 or etanercept with a flow of 2.5 mg/ml/1μl/h for 3 consecutive days, as previously described ([@B63]).

In addition, intracerebroventricular (i.c.v.) injection of saline, XPro1595, or etanercept was performed 30 min after pMCAO. For i.c.v. delivery, animals were fixed in a stereotactic frame (David Kopf Instruments, United States) immediately after pMCAO, and anesthesia was maintained with isoflurane (2% isoflurane in O~2~). One single i.c.v. injection (0.5 μl) of either saline, XPro1595 (1.25 mg/kg), or etanercept (1.25 mg/kg) was administered using a 2 μl Hamilton micro-syringe. The injection was made in the left lateral ventricle using the following coordinates with reference to bregma: anterior -0.2 mm; lateral 0.9 mm; ventral 2.5 mm; tooth-bar -1.0 mm. After injection, the syringe was left in place for a further 5 min before being slowly retracted.

Group Size and Study Design {#S2.SS4}
---------------------------

Groups of mice for infarct volumetric, functional, and inflammatory analyses consisted of mice treated topically for 1 day (*n* = 7--11/group) or for 3 days (*n* = 20/group) or mice treated i.c.v. for 1 day (*n* = 6--7/group) or for 3 days (*n* = 20/group) after pMCAO. Animals were excluded from the study if the infarct volume was less than 3 mm^3^ due to lack of successful occlusion of the MCA. Animals with MCA bleedings were excluded due to hematoma formation. A total of 29 mice subjected to pMCAO were excluded due to lack of infarct or bleedings.

To evaluate microglial and leukocyte profiles, a group of sham-treated mice were allowed to survive 3 days (*n* = 5/group). Mice allowed to survive for 1 day (*n* = 5--6/group) or 3 days (*n* = 5/group) after pMCAO were included for flow cytometric studies.

Mortality was 9% and independent of treatment. In total, in the day one groups, 2 mice treated topically with saline, 1 mouse treated topically with XPro1595, 1 mouse treated i.c.v. with XPro1595, and 1 mouse treated i.c.v. with etanercept died. In the day 3 groups, 1 mouse with 3 days survival treated topically with saline, 2 mice treated topically with XPro1595, and 1 mouse treated topically with etanercept, 2 mice treated i.c.v. with saline, 1 mouse treated i.c.v. with XPro1595, and 3 mice treated i.c.v. with etanercept died.

Behavioral Tests {#S2.SS5}
----------------

Functional outcome was evaluated using the Hargreaves test (2 days after surgery) and a grip strength test (3 days after surgery). Prior to behavioral testing, mice were allowed to acclimatize in the behavior room. Neuromuscular testing of mice with mini-osmotic pumps was not possible as the pumps were placed in subcutaneous pockets on the lateral back of the mice and affected the animals' balance. Behavioral testing was therefore only performed with i.c.v. treated mice.

### Thermal Nociception Assay {#S2.SS5.SSS1}

Thermal hyperalgesia was evaluated using the Hargreaves nociception assay ([@B30]). The plantar test (37370, Ugo Basile, Comerio VA, Italy) was used to measure the withdrawal latencies after predisposing the hind paws to heat ([@B13]). Five measurements were registered for each hind paw prior to and 2 days after pMCAO; the lowest and highest values were excluded, and the mean was calculated. Data are presented as symmetry between contra- and ipsilateral hind paws prior to and after surgery. The mice were allowed to recover for 15 min between trials. Mice were excluded if they did not complete all the trials. In total, four animals were excluded.

### Grip Strength {#S2.SS5.SSS2}

Grip strength was measured 1 day prior to and 3 days after surgery using a grip strength meter (BIO-GT-3, BIOSEB, Vitrolles, France). We measured the peak force generated when the mouse loosened its grip when being gently pulled horizontally backwards. We tested both the front right (R) and the front left (L) paw as well as the total grip strength. The peak force (g) of five trials was recorded, and the highest score was registered. Results are presented as delta (Δ) grip strength in grams (g), representing the difference in grip strength prior to and after pMCAO ([@B43]; [@B11]). Mice were excluded if they could not complete the trials with both paws separately and together. A total of four mice were excluded.

Tissue Processing {#S2.SS6}
-----------------

### Fresh Frozen Tissue {#S2.SS6.SSS1}

Animals were sacrificed by cervical dislocation 1 or 3 days after induction of ischemia. Brains were dissected, frozen in CO~2~ snow, and stored at −80°C until further processing. Brains were cut into six parallel series of 30 μm thick sections as previously described ([@B11]).

### Flow Cytometric Tissue {#S2.SS6.SSS2}

Mice treated topically with saline, XPro1595, or etanercept were sacrificed 1 or 3 days after pMCAO or 3 days after sham surgery. All mice were given an overdose of pentobarbital (200 mg/ml) containing lidocaine hydrochloride (20 mg/ml) (Glostrup Apotek, Glostrup, Denmark) and perfused through the left ventricle with phosphate buffered saline (PBS, pH 7.4). Ipsilateral and contralateral cortices were dissected and placed in Hanks' balanced salt solution (HBSS) containing 10% fetal bovine serum (FBS). Lymph nodes were collected for positive detection of T cells. A pool of cells collected from ipsilateral cortices was used for fluorescence minus one (FMO), and isotype controls and a contralateral pool with cells from lymph nodes for compensation. Live/dead cell staining was performed using eBioscience Fixable Viability Dye eFluor 506 (Thermo Fisher Scientific, Roskilde, Denmark).

The tissue was mechanically dissociated using 70 μm cell strainers (BD Biosciences) as previously described ([@B53]). Samples were washed with FACS buffer containing HBSS, 2% FBS, and 0.1% sodium azide, fixed with BD Cytofix/Cytoperm (BD Biosciences) and blocked for non-specific binding using 50 μg/ml Syrian Hamster Gamma Globulin (Trichem) and Mouse BD Fc Block (BD Biosciences) diluted in FACS buffer. For detection of microglia and leukocytes, cells were incubated with CD45-PerCP-Cy5.5 (clone 30-F11) and CD11b-PE (clone M7/70).

For separation of macrophages and granulocytes, the following antibodies were used: Ly6C-PE-Cy7 (clone AL21) and Ly6G-BV421 (clone 1A8). T cells were detected with CD3-APC (clone 145-2C11). Respective isotype controls were: IgG2b-PerCP-Cy5.5 (clone A95-1), IgG2b-PE (clone A95-1), IgM-PE-Cy7 (clone R4-22), IgG2a-BV421 (clone R35-95), and IgG1κ-APC (clone A19-3). All antibodies were from BD Biosciences. Flow cytometry was performed as previously described using FACSVerse (BD Biosciences) and analyzed by FACSuite software ([@B11]). Positive staining for CD45^dim^CD11b^+^ microglia, CD45^high^CD11b^+^LY6C^+^Ly6G^--^ macrophages, CD45^+^CD3^+^ T cells, and CD45^high^CD11b^+^Ly6C^+^Ly6G^+^ granulocytes was determined based on FMO controls and intensity of the respective isotype control as previously described ([@B12]; [@B53]). A total of 1,000,000 events were collected using side scatter (SSC). The mean fluorescence intensity (MFI) was calculated as the geometric mean of each population.

### Infarct Volumetric and Rostrocaudal Distribution Analysis {#S2.SS6.SSS3}

Every sixth section was stained with Toluidine blue, and infarct volume was estimated based on Cavalieri's principle for volume estimation as previously described ([@B27]; [@B43]). The rostrocaudal distribution of the infarct was estimated 3,600 μm anterior of the anterior commissure to 3,600 μm posterior of the anterior commissure as previously described ([@B12]; [@B53]).

Real-Time Polymerase Chain Reaction (RT-PCR) {#S2.SS7}
--------------------------------------------

One series of brain tissue was used for RT-PCR. The RNA was extracted using the TRIzol (Invitrogen) method as previously described ([@B56]). Purity of RNA was controlled spectrophotometrically with 260/280 and 230/260 values using NanoDrop (Thermo Fisher Scientific). Degradation of RNA was measured by RNA integrity factor (RIN) using Agilent 2100 Bioanalyzer (Agilent Genomics). Samples were used for PCR if they had a RIN factor of 7.6 or above. RNA was reverse transcribed into complementary DNA (cDNA) according to the High-Capacity cDNA Reverse Transcription kit protocol (Applied Biosystems). PCR was performed according to the Maxima SYBR Green/ROX qPCR Master Mix (2X) (Thermo Fisher Scientific) protocol. Primer sequences used for RT-PCR ([Table 1](#T1){ref-type="table"}) were designed to target exon-exon junctions whenever possible. Primers were ordered from TAG Copenhagen. Values were normalized to hypoxanthine phosphoribosyltransferase 1 (HPRT1) mRNA, and relative values were calculated relative to a calibrator pool of unmanipulated mice as previously described ([@B56]).

###### 

Primer sequences for RT-PCR.

  **Gene**   **Primer sequence**                    **Product length**
  ---------- -------------------------------------- --------------------
  CD11b      F: 5′ cggaaagtagtgagagaactgtttc 3′     114 bp
             R: 5′ cttataatccaagggatcaccgaattt 3′   
  CX3CR1     F: 5′ cctgcctctgagaaatggag 3′          332 bp
             R: 5′ atctctccagcccctgaaat 3′          
             F: 5′ cagcatcgaccggtacctt 3′           65 bp
             R: 5′ gctgcactgtccggttgtt 3′           
  Arg1       Mm00475988_m1 from Life technologies   65 bp
  CCL2       F: 5′ ccccactcacctgctgctac 3′          86 bp
             R: 5′ cctgctgctggtgattctctt 3′         
  CXCL10     F: 5′ gccgtcattttctgcctcatcct 3′       113 bp
             R: 5′ ctcattctcactggcccgtcatc 3′       
  CXCL1      F: 5′ catggctgggattcacctcaag 3′        113 bp
             R: 5′ ggcaagcctcgcgaccattct 3′         
  TREM2      F: 5′ cagccctgtcccaagccctcaac 3′       134 bp
             R: 5′ ctcctcacccagctgccgacacc 3′       
  P2RY12     F: 5′ tctttgctgggctcatcacgaa 3′        167 bp
             R: 5′ aggcccggctcccagtttag 3′          
  iNOS       F: 5′ ggacagcacagaatgttccagaa 3′       104 bp
             R: 5′ caaaatctctccactgccccag 3′        
  IL-1β      F: 5′ tgtaatgaaagacggcacac 3′          68 bp
             R: 5′ tcttctttgggtattgcttgg 3′         
  TNFR1      F: 5′ gcccgaagtctactccatcatttg 3′      91 bp
             R: 5′ ggctggggagggggctggagttag 3′      
  TNFR2      F: 5′ gcccagccaaactccaagcatc 3′        133 bp
             R: 5′ tcctaacatcagcagacccagtg 3′       
  HPRT1      F′: 5′-aagcagtacagccccaaaatg-3′        
             R′: 5′-aaatccaacaaagtctggcctgta-3′     

F, forward; R, reverse.

Cytokine and Receptor Protein Expression and Drug Concentration Analysis {#S2.SS8}
------------------------------------------------------------------------

One series of brain tissue was lysed in Complete Mesoscale buffer according to the manufacturer's protocol (Mesoscale Discovery, Rockville, MD, United States). Protein concentrations were determined according to the protocol from Micro BCA protein assay kit (Thermo Fischer Scientific). Cytokine and chemokine concentrations were estimated using an MSD Mouse Pro-Inflammatory V-Plex Plus Kit (Mesoscale Discovery) and TNF receptor concentrations using the Mouse TNF-RI and TNFR-II Ultra-Sensitive Kits (Mesoscale Discovery). XPro1595 levels were measured in ischemic brain tissue lysates using a human TNF V-Plex immunoassay (Mesoscale Discovery) as previously described ([@B37]). The standard in the kit was replaced with XPro1595, which was diluted in the kit diluent number 2. Etanercept levels were measured using a human TNFRII Ultra-Sensitive immunoassay (Mesoscale Discovery) ([@B37]). The standard in the kit was replaced with etanercept diluted in the kit diluent number 2. All kits were read on a SECTOR Imager 6000 plate reader (Mesoscale Discovery) according to the manufacturer's instructions. All samples were run in duplex, and coefficient of variation (CV) values below 25% were accepted.

Characterization of Cells From Mice With Genetic Ablation of SolTNF {#S2.SS9}
-------------------------------------------------------------------

### Cell Purification for Proteomics {#S2.SS9.SSS1}

Microglia and neurons were purified from cortices from adult (8 weeks) tmTNF^Δ/Δ^ and tmTNF^wt/wt^ mice by MACS affinity-based cell sorting (Miltenyi Biotech, Bergisch-Gladbach, Germany) as previously described ([@B13]). Mice were sacrificed by cervical dislocation, cortices dissociated with Neuronal dissociation papain kit (P) (Miltenyi Biotech) and microglia and neurons purified according to the manufacturer's protocol. The cell suspensions were incubated with monoclonal CD11b beads (Miltenyi Biotech) and applied to LS magnetic separation columns (Miltenyi Biotech) attached to a magnetic field for positive selection of microglia. The flow through was further incubated with Neuron Isolation Kit (Miltenyi Biotech) and applied to LD magnetic separation columns (Miltenyi Biotech) for negative selection of neurons. The cell pellets were stored at −80°C until preparation for mass spectrometry.

### Sample Preparation/Digestion for Mass Spectrometry {#S2.SS9.SSS2}

Microglia and neurons were prepared using a filter-aided sample preparation protein digestion protocol essentially according to [@B41]. Briefly, samples were lysed in cold lysis buffer (5% sodium deoxycholate, 50 mM triethylammonium bicarbonate, pH 8.5) and homogenized by bead beating (Bullet Blender Gold (NextAdvance, United States); 0.9--2.0 mm steel bead blend; Setting 10; 2 × 5 min; +4°C) and heat-denaturized at 95°C for 5 min. Protein concentrations were estimated using a NanoDrop 1000 UV-Vis spectrophotometer (Thermo Fisher Scientific) using bovine serum albumin as reference standard. Protein lysate was transferred to a 10 kDa molecular weight cutoff spin-filter (Millipore, Billerica, MA, United States) and protein disulfide bonds were reduced with 10 mM tris(2-carboxyethyl)phosphine (Thermo Fisher Scientific) for 30 min. Afterward, cysteine residues were blocked with 50 mM chloroacetamide (Sigma-Aldrich, St. Louis, MO, United States) for 30 min in the dark. Protein digestion was performed with sequencing grade modified trypsin (Promega, Madison, WI, United States) at an enzyme to substrate ratio of 1:50 (w/w) for 16 h at 37°C. The peptide material was eluted from the spin-filter, acidified with trifluoroacetic acid to a final concentration of 1% and purified by phase inversions with ethyl acetate 1:2 (v/v). The peptide rich aqueous phase was dried down in a vacuum centrifuge.

### UPLC-MS/MS Sample Analysis {#S2.SS9.SSS3}

Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis was performed using an UltiMate 3000 UPLC system (Thermo Fisher Scientific) coupled online to a Q Exactive HF mass spectrometer (Thermo Fisher Scientific). Peptide material was separated on a 75 cm C18 Acclaim PepMap100 analytical column (Thermo Fisher Scientific) with 96% solvent A (0.1% FA) and 4% solvent B (0.1% FA in acetonitrile), which was increased to 30% solvent B on a 60 min ramp gradient at a constant flow rate of 250 nL/min. Eluting peptides were introduced directly into the mass spectrometer by a picotip emitter for electrospray ionization (New Objective, Woburn, MA, United States).

The mass spectrometer was operated in positive mode using a data-dependent TOP12 acquisition method with the following settings: mass range m/z 400--1200; isolation window m/z 1.6; NCE 27; charge state exclusion: unassigned, 1, \>6; peptide match preferred; dynamic exclusion 30 s.

### Protein Quantification and Filtering {#S2.SS9.SSS4}

The .RAW files were investigated by Progenesis QI for Proteomics to access the chromatographic quality. The raw data were searched with two complementary label free quantitative approaches: MaxQuant (v1.5.6.0) against the UniProt Mouse reference proteome database with isoforms (UP000000589, November 2016). Standard settings were employed in MaxQuant, including max two tryptic missed cleavages, and a first search with 20 ppm mass tolerance followed by data calibration and a main search with 4.5 ppm mass tolerance. The match between runs feature was enabled to allow the transfer of identified precursors between different runs, based on accurate mass and retention time. The following peptide modifications were found to be abundant with the applied protocol and were included in the search: carbamidomethylated cysteine residues (fixed), acetylation of the N-terminal of proteins (variable), oxidation of methionine (variable). Identified proteins and peptide spectral matches were filtered to \<1% false discovery rate (FDR) using a forward/reverse database search strategy in MaxQuant, and proteins tagged as common contaminants were removed. Relative protein quantities were calculated by summing the unique peptide peak areas of each protein in MaxQuant using the LFQ (label-free quantitation) feature. Additional filtering steps were employed in Perseus (v1.5.6.0): (1) The quantitation of any protein was required to be based on at least two unique peptides. (2) Unique peptides were required to be quantifiable in at least three of the tmTNF^wt/wt^ or tmTNF^Δ/Δ^ samples. (3) Pearson's correlation coefficients (R) between the technical repeats should be greater than 0.95, based on log2 transformed protein LFQ values.

### Data Processing {#S2.SS9.SSS5}

All abundances were log2-transformed and proteins with less than two unique peptides and (\>50% missing values) filtered out. Proteins with a statistically significant mean abundance difference between the tmTNF^wt/wt^ and tmTNF^Δ/Δ^ samples were identified by independent two-sample t-tests in Perseus, with permutation-based truncation using standard parameters (s0 = 0.1, 250 randomizations) to correct for multiple hypothesis testing. In this way, the p-value requirement was adjusted to expect \<5% false positives among the statistically significant findings.

The MS data has been deposited to the ProteomeXchange Consortium^[1](#footnote1){ref-type="fn"}^ via the PRIDE partner repository with dataset identifiers PXD014440. Protein-protein interaction analysis was performed by STRING^[2](#footnote2){ref-type="fn"}^.

Phagocytosis Assay {#S2.SS10}
------------------

In order to test phagocytic activity of primary microglia derived from tmTNF^wt/wt^ and tmTNF^Δ/Δ^ mice, the microglia were plated, activated and incubated with fluorescent beads. As a measure of phagocytic activity, the number of engulfed beads was counted and morphological changes estimated as previously described ([@B1]; [@B22]). Microglial cultures were prepared using brain tissue from tmTNF^Δ/Δ^ (*n* = 3) and tmTNF^wt/wt^ (*n* = 6) pups at post-natal age 5--7. The meninges and blood vessels were removed, and brains collected in ice-cold HBSS without Ca^2+^ and Mg^2+^ (Thermo Fisher Scientific) under sterile conditions. Cortices were processed using Neural Tissue Dissociation Kit (P) (Miltenyi Biotech) according to the manufacturer's protocol. Cell suspensions were filtered through 70 μm cell strainers (BD Biosciences, San Jose, CA, United States) and washed with HBSS with Ca^2+^ and Mg^2+^ (Thermo Fisher Scientific). Cell suspensions were centrifuged, and the pellet used for MACS sorting. Microglia were purified by MACS sorting using magnetic CD11b^+^ beads on LS columns (Miltenyi Biotech) and cultured in culture medium A (76 % Dulbecco's modified Eagle's medium (DMEM) (Thermo Fisher Scientific), 20% FBS (Thermo Fisher Scientific), 1% minimum essential media (MEM) (Thermo Fisher Scientific), 1% penicillin streptomycin (Thermo Fisher Scientific), 1% Glutamax^TM^ (Gibco, Thermo Fisher Scientific), 1% pyruvate (Thermo Fisher Scientific)) on poly-L-ornithine-coated plates in a humified CO~2~ incubator at 37°C. After 3 days half of the media was changed to culture medium B (86% DMEM, 10% FBS, 1% MEM, 1% penicillin streptomycin, 1% Glutamax^TM^, 1% pyruvate). Four days after the media change microglia were activated by adding 100 ng/mL LPS (Invitrogen, Thermo Fisher Scientific) for 24 h. After activation, FluoSpheres^TM^ Carboxylate-Modified Microspheres (1.0 μm, 505/515, yellow-green fluorescent) (Thermo Fisher Scientific) were added onto the cultured cells. After 2 h phagocytosis was terminated by adding cold culture medium B. Cells were fixed with 4% paraformaldehyde, blocked in 5% normal goat serum in tris-buffered saline and incubated overnight in anti-Iba1 antibody (1:500, Fujifilm Wako Pure Chemical Corporation, Japan). The next day, cells were stained using alexa 594-conjugated anti-rabbit antibody (1:750, Alexa594 Molecular Probes) (Thermo Fisher Scientific) and 4′,6-diamidino-2-phenylindol (DAPI) (Thermo Fisher Scientific). Pictures were taken using a FV1000 (Olympus) confocal microscope from nine randomly chosen positions per coverslip. Analysis of phagocytosis measured as engulfed beads/cell and cell morphology measured as cell area, membrane irregularity and perimeter length was done by automated counting software Puntomorph^[3](#footnote3){ref-type="fn"}^ ([@B1]).

Statistical Analysis {#S2.SS11}
--------------------

Data are presented as mean ± SEM. Statistical comparison between the three groups (saline, Xpro1595, and etanercept) was assessed by one-way ANOVA followed by Tukey's *post hoc* test (GraphPad Prism Software Inc., San Diego, CA, United States). Comparison of the rostrocaudal distribution of the infarct and comparison of phagocytosis in tmTNF^Δ/Δ^ and tmTNF^wt/wt^ microglia were tested by two-way ANOVA followed by Tukey's *post hoc* test. Statistical significance of the asymmetry of the paws in the grip strength test and the Hargreaves nociception test was tested by Student's paired *t*-test. Normal distribution of variables was tested using both Brown-Forsythe and Bartlett's tests. Significance was set at *p* ≤ 0.05.

Results {#S3}
=======

Topical Delivery of XPro1595 Decreases Infarct Volume 1 and 3 Days After pMCAO {#S3.SS1}
------------------------------------------------------------------------------

Infarct volumes were estimated in Toluidine blue-stained brain sections from mice treated topically or i.c.v. with saline, XPro1595, or etanercept and allowed to survive 1 or 3 days after pMCAO ([Figure 1](#F1){ref-type="fig"} and [Supplementary Figure 1A](#FS1){ref-type="supplementary-material"}). At day 1, infarct volumes were significantly reduced in mice treated topically with XPro1595 compared to mice treated topically with saline ([Figure 1B](#F1){ref-type="fig"}). Etanercept treatment showed no effect. The rostrocaudal distribution of the infarcts was comparable between groups ([Figure 1C](#F1){ref-type="fig"}). At day 3, infarct volumes were also significantly reduced in mice treated topically with XPro1595 ([Figure 1E](#F1){ref-type="fig"}). Again, the rostrocaudal distribution of the infarct was comparable between groups ([Figure 1F](#F1){ref-type="fig"}).

![Infarct volume and rostrocaudal distribution after topical administration of TNF inhibitors. **(A)** Toluidine blue-stained brain sections of mice treated topically with saline, XPro1595, or etanercept and allowed to survive 1 day after pMCAO. Scalebar 500 μm. **(B)** Infarct volume estimation 1 day after pMCAO. N(saline) = 11; n(XPro1595) = 6; n(etanercept) = 4. **(C)** Rostrocaudal distribution of the infarct 1 day after pMCAO. **(D)** Toluidine blue-stained brain sections of mice treated topically with saline, XPro1595, or etanercept and allowed to survive 3 days after pMCAO. **(E)** Infarct volume estimation 3 days after pMCAO. N(saline) = 12; n(XPro1595) = 15; n(etanercept) = 17. **(F)** Rostrocaudal distribution of the infarct 3 days after pMCAO. ^\*^*p* ≤ 0.05, one-way ANOVA followed by Tukey's *post hoc* test.](fnins-13-00781-g001){#F1}

Intracerebroventricular administration of XPro1595 or etanercept was not effective in decreasing infarct size ([Supplementary Figure 1A](#FS1){ref-type="supplementary-material"}). In support of this, we observed no difference in functional outcomes as assessed by the Hargreaves thermal hyperalgesia ([Supplementary Figure 1B](#FS1){ref-type="supplementary-material"}) or grip strength tests ([Supplementary Figures 1C,D](#FS1){ref-type="supplementary-material"}), except for a total weaker grip strength on day 3 compared to baseline in mice treated with etanercept ([Supplementary Figure 1D](#FS1){ref-type="supplementary-material"}).

XPro1595 and Etanercept Can Be Detected in Brain Ischemic Tissue {#S3.SS2}
----------------------------------------------------------------

To validate the presence of XPro1595 and etanercept and estimate their concentrations in the ischemic brain following topical and i.c.v. delivery, we measured the concentration of XPro1595 and etanercept 1 day after pMCAO ([Figures 2A,B](#F2){ref-type="fig"}). We found topical administration to be an efficient method to deliver a high concentration of XPro1595 to neural tissue ([Figure 2A](#F2){ref-type="fig"}). After topical administration, the concentration of XPro1595 in brain tissue 1 day after pMCAO was 630,300 ± 160,000 pg/mg. The concentration of XPro1595 was lower after i.c.v. administration, with a mean of 69,400 ± 51,300 pg/mg ([Figure 2A](#F2){ref-type="fig"}). This concentration in the neural tissue is, however, sufficient to neutralize solTNF and to promote neuroprotection, based on previous publications in an animal model of Alzheimer's disease ([@B52]).

![Detection of TNF inhibitors in ischemic brain tissue 24 h after pMCAO. **(A)** Concentration of XPro1595 in brain tissue after topical and i.c.v. administration. *N* = 4--7/group (excluded due to too high CV values: saline pump, *n* = 4; saline i.c.v., *n* = 2). **(B)** Concentration of etanercept in brain tissue after topical and i.c.v. administration. *N* = 2--6/group (excluded due to too high CV values: saline i.c.v., *n* = 2; XPro1595 i.c.v., *n* = 1).](fnins-13-00781-g002){#F2}

Etanercept was detected in the brain tissue after both delivery routes ([Figure 2B](#F2){ref-type="fig"}). The concentration of etanercept in brain tissue 1 day after pMCAO was 1,600 pg/mg after topical administration and 1,500 ± 200 pg/mg after i.c.v. administration. This demonstrated that both XPro1595 and etanercept successfully accessed the ischemic brain tissue.

Topical Treatment With XPro1595 Does Not Affect Microglial and Leukocyte Cell Populations After pMCAO {#S3.SS3}
-----------------------------------------------------------------------------------------------------

To investigate potential changes in microglial and leukocyte populations in mice subjected to pMCAO and treated topically with saline, XPro1595 or etanercept, we performed flow cytometry and gated for CD45^dim^CD11b^+^ microglia, CD45^dim^CD11b^+^Ly6C^+^Ly6G^--^ macrophages, CD45^dim^CD11b^+^Ly6C^+^Ly6G^+^ granulocytes ([Figure 3A](#F3){ref-type="fig"}), and CD45^+^CD3^+^ T cells.

![Flow cytometric analysis of ipsilateral hemispheres in sham and pMCAO mice after topical saline, XPro1595, or etanercept treatment**. (A)** Gating strategy for CD45^+^ cells, CD45^dim^CD11b^+^ microglia, CD45^high^CD11b^+^ leukocytes, CD45^high^CD11b^+^Ly6C^+^Ly6G^--^ macrophages, and CD45^high^CD11b^+^Ly6C^+^Ly6G^+^ granulocytes. **(B--D)** Changes in CD45^dim^CD11b^+^ microglia presented as % of CD45^+^ cells 3 days after sham surgery or 1 or 3 days after pMCAO. **(E--G)** Changes in CD45^high^CD11b^+^Ly6C^+^Ly6G^--^ macrophages presented as % of CD45^+^ cells after sham surgery or 1 or 3 days after pMCAO. **(H--J)** Changes in CD45^high^CD11b^+^Ly6C^+^Ly6G^+^ granulocytes presented as % of CD45^+^ cells after sham surgery or 1 or 3 days after pMCAO. **(K--M)** Changes in CD3^+^ T cells presented as % of CD45^+^ cells after sham surgery or 1 or 3 days after pMCAO. N(sham) = 3--5/group; n(day 1) = 4--5/group; n(day 3) = 5/group; ^\*^*p* ≤ 0.05; one-way ANOVA followed by Tukey's *post hoc* test.](fnins-13-00781-g003){#F3}

We found that compared to saline, both Xpro1595 and etanercept treatment increased the percentage of microglia in the ipsilateral cortex 3 days after sham surgery ([Figure 3B](#F3){ref-type="fig"}), whereas no difference was observed between groups at day 1 ([Figure 3C](#F3){ref-type="fig"}) or day 3 ([Figure 3D](#F3){ref-type="fig"}) after pMCAO. In all groups of mice 3 days after pMCAO, the microglial population constituted ∼80% of all live CD45^+^ cells in the contralateral cortex, with only ∼60% in sham. By 1 day after pMCAO the microglial population constituted ∼60% of all live CD45^+^ cells ([Supplementary Figures 2A--C](#FS1){ref-type="supplementary-material"}). The percentage of infiltrating macrophages ([Figures 3E--G](#F3){ref-type="fig"}), granulocytes ([Figures 3H--J](#F3){ref-type="fig"}), and T cells ([Figures 3K--M](#F3){ref-type="fig"}) did not differ between groups at any time point investigated, although the percentages of cells increased over time in the ipsilateral cortex ([Figures 3E--M](#F3){ref-type="fig"}) and remained relatively constant in the contralateral cortex ([Supplementary Figures 2D--L](#FS1){ref-type="supplementary-material"}).

Since microglia and macrophages upregulate their expression of CD11b and CD45 after ischemia ([@B34]; [@B65]; [@B14]; [@B60]), their activation status was evaluated based on the MFI of these cell surface markers. MFIs of CD11b and CD45 were comparable between treatment groups 3 days after sham surgery and 1 and 3 days after pMCAO ([Supplementary Figures 3A--L](#FS1){ref-type="supplementary-material"}). However, both microglia and leukocytes seemed to downregulate their expression of CD11b and upregulate their expression of CD45 3 days after pMCAO, which was not the case in sham mice and 1 day after pMCAO ([Supplementary Figures 3A--L](#FS1){ref-type="supplementary-material"}, please compare C to A and B; I to G and H; F to D and E; and L to J and K).

XPro1595 Affects Microglial Activation {#S3.SS4}
--------------------------------------

We next investigated changes in mRNA expression of selected microglial/macrophage and inflammatory markers in brain tissue derived from mice subjected to pMCAO and treated topically ([Figure 4](#F4){ref-type="fig"}) or i.c.v. ([Supplementary Figure 4](#FS1){ref-type="supplementary-material"}) with saline, XPro1595, or etanercept and allowed to survive 1 or 3 days after pMCAO.

![Inflammatory gene profile 1 and 3 days after pMCAO in mice treated topically with saline, XPro1595, or etanercept. mRNA expression of cytokines, pro-inflammatory molecules, chemokines, and microglial markers presented as % of gene expression in saline-treated animals **(A--M). (A)** Expression of *Tnf* mRNA. **(B)** Expression of *Tnfrsf1a* (TNFR1) mRNA. **(C)** Expression of *Tnfrsf1b* (TNFR2) mRNA. **(D)** Expression of *Il1β* mRNA. **(E)** Expression of *Nos2* (iNOS) mRNA. **(F)** Expression of *Cxcl1* mRNA. **(G)** Expression of *Cxcl10* mRNA. **(H)** Expression of *Ccl2* mRNA. **(I)** Expression of *Cx3cr1* mRNA. **(J)** Expression of *P2ry12* mRNA. **(K)** Expression of *Trem2* mRNA. **(L)** Expression of *CD11b* mRNA. **(M)** Expression of *Arg1* mRNA. N(day 1) = 4--11/group, n(day 3) = 5--6/group; ^\*^*p* ≤ 0.05, ^∗∗^*p* ≤ 0.01, ^∗∗∗^*p* ≤ 0.001, ^\*\*\*\*^*p* ≤ 0.0001; one-way ANOVA followed by Tukey's *post hoc* test.](fnins-13-00781-g004){#F4}

We found *Tnf* mRNA expression to be significantly upregulated 1 and 3 days after pMCAO in mice treated topically with XPro1595 when compared to saline- and etanercept-treated mice ([Figure 4A](#F4){ref-type="fig"}). *Tnfrsf1a* (TNFR1, [Figure 4B](#F4){ref-type="fig"}) and *Tnfrsf1b* (TNFR2, [Figure 4C](#F4){ref-type="fig"}) mRNA expression was comparable between treatment groups at both days 1 and 3 after pMCAO. At 3 days, *Il-1beta* mRNA levels were significantly upregulated in mice treated topically with XPro1595 compared to saline- and etanercept-treated mice ([Figure 4D](#F4){ref-type="fig"}), whereas no significant changes in *Nos2* (iNOS) mRNA expression was observed between groups, although XPro1595 tended to downregulate the expression at 3 days (*p* = 0.08; [Figure 4E](#F4){ref-type="fig"}).

To study whether TNF inhibition using XPro1595 or etanercept affects chemokine gene expression, we measured the mRNA levels of *Cxcl1*, *Cxcl10*, and *Ccl2* at 1 and 3 days after pMCAO. Topical etanercept treatment significantly increased *Cxcl1* mRNA compared to saline and XPro1595 at day 1 and compared to XPro1595 at day 3 after pMCAO ([Figure 4F](#F4){ref-type="fig"}). In contrast, *Cxcl10* mRNA levels decreased at day 3 in mice treated topically with etanercept compared to saline ([Figure 4G](#F4){ref-type="fig"}), and *Ccl2* mRNA levels significantly increased at day 3 in XPro1595-treated mice compared to both saline- and etanercept-treated mice ([Figure 4H](#F4){ref-type="fig"}).

We further measured mRNA expression levels of microglial/macrophage markers *Cx3cr1*, *P2ry12*, *Trem2*, *Cd11b*, and *Arg1*. We found that at days 1 and 3 after pMCAO, topical XPro1595 treatment decreased *Cx3cr1* mRNA expression compared to saline-treated mice ([Figure 4I](#F4){ref-type="fig"}). In contrast, *P2ry12* mRNA expression was significantly increased at 1 day after pMCAO in topically XPro1595-treated mice compared to saline-treated mice ([Figure 4J](#F4){ref-type="fig"}), as well as *Trem2* mRNA expression at 1 and 3 days after pMCAO ([Figure 4K](#F4){ref-type="fig"}). *Cd11b* and *Arg1* mRNA levels were comparable between groups except for a significant decrease in *Arg1* mRNA levels in XPro1595-treated mice at day 3 ([Figures 4L,M](#F4){ref-type="fig"}).

Even though i.c.v. administration of TNF inhibitors had no effect on infarct volume or functional outcome, we also investigated potential changes in mRNA expression after i.c.v. injection of XPro1595 or etanercept ([Supplementary Figure 4](#FS1){ref-type="supplementary-material"}). We observed no change in *Tnf*, *Tnfrsf1a*, *Tnfrsf1b*, *Il-1beta*, *Nos2*, *Cxcl1*, *Cx3cr1*, or *CD11b* mRNA expression between groups. Etanercept significantly increased *Cxcl10* mRNA levels compared to saline at day 1 and compared to both XPro1595 and saline 3 days after pMCAO ([Supplementary Figure 4](#FS1){ref-type="supplementary-material"}). Also, *P2ry12* mRNA levels increased significantly at day 1 in etanercept-treated mice compared to saline- and Xpro1595-treated mice, and *Ccl2* and *Trem2* mRNA levels increased significantly at day 3, while *Arg1* decreased significantly.

Cytokine, Chemokine, and TNF Receptor Expression in Brain Tissue 1 and 3 Days After TNF Inhibitor Treatment {#S3.SS5}
-----------------------------------------------------------------------------------------------------------

To study whether topical ([Figure 5](#F5){ref-type="fig"}) or i.c.v. ([Supplementary Figure 5](#FS1){ref-type="supplementary-material"}) XPro1595 and etanercept treatment after pMCAO affected cytokines, TNF receptor and/or chemokine protein levels, we measured TNF, TNFR1, TNFR2, IL-1β, CXCL1, IL-6, IL-10, IL-4, IL-5, and IL-12p70 levels in brain tissue 1 day after pMCAO, when neuroinflammation is maximal ([@B42]), in addition to 3 days after pMCAO using multiplex ELISA.

![Cytokine and TNF receptor protein expression in brain tissue 1 and 3 days after pMCAO in mice treated topically with saline, XPro1595, or etanercept. **(A)** Expression of TNF (*n* = 4--11/group). **(B)** Expression of TNFR1 (*n* = 4--11/group). **(C)** Expression of TNFR2 (*n* = 4--10/group). **(D)** Expression of IL-1β (*n* = 3--11/group). **(E)** Expression of CXCL1 (*n* = 3--11/group). **(F)** Expression of IL-6 (*n* = 3--9/group). **(G)** Expression of IL-10 (*n* = 3--10/group). **(H)** Expression of IL-4 (*n* = 2--11/group). **(I)** Expression of IL-5 (*n* = 4--10/group). **(J)** Expression of IL-12p70 (*n* = 4--11/group). ^∗∗^*p* ≤ 0.01; one-way ANOVA with Tukey's *post hoc* test.](fnins-13-00781-g005){#F5}

We found that despite increased *Tnf* mRNA expression after topical XPro1595 treatment, the protein expression tended to be downregulated in XPro1595-treated mice (*p* = 0.06, [Figure 5A](#F5){ref-type="fig"}), whereas TNF levels in etanercept-treated mice were comparable to saline-treated mice 1 day after pMCAO. At 3 days, TNF levels had increased significantly in etanercept-treated mice compared to saline-treated mice. Compared to topical saline treatment, etanercept treatment downregulated TNFR1 levels at day 1, which also showed tendency to be downregulated after XPro1595 treatment (*p* = 0.08), whereas TNFR1 levels were comparable at 3 days ([Figure 5B](#F5){ref-type="fig"}). Topical treatment had no effect on expression of TNFR2, IL-1β, Cxcl1, IL-6, IL-10, IL-4, IL-5, or IL-12p70 ([Figures 5C--J](#F5){ref-type="fig"}).

Intracerebroventricular administration of TNF inhibitors showed no effect on the TNF or TNFR1 protein expression ([Supplementary Figures 5A,B](#FS1){ref-type="supplementary-material"}) although TNFR2 was downregulated after etanercept-treatment compared to saline treatment 1 day after pMCAO ([Supplementary Figure 5C](#FS1){ref-type="supplementary-material"}). Treatment with XPro1595 showed a tendency toward reducing TNFR2 levels at day 1 after pMCAO (*p* = 0.07) ([Supplementary Figure 5C](#FS1){ref-type="supplementary-material"}). At 1 day after pMCAO, etanercept treatment significantly increased IL-1β levels compared to saline ([Supplementary Figure 5D](#FS1){ref-type="supplementary-material"}), but no effect was observed on CXCL1, IL-6, IL-10, IL-4, IL-5, or IL-12p70 levels ([Supplementary Figures 5E--J](#FS1){ref-type="supplementary-material"}).

tmTNF Microglia Have an Upregulated Expression of Phagocytosis-Related Proteins {#S3.SS6}
-------------------------------------------------------------------------------

In order to investigate the hypothesis that ablation of solTNF improves microglial phagocytosis, we investigated differentially expressed proteins in microglia derived from tmTNF^Δ/Δ^ and tmTNF^wt/wt^ mice using mass spectrometry. In total, 1,564 proteins with two or more unique peptides were quantified by label free quantification in microglia cells ([Supplementary Table 1](#TS1){ref-type="supplementary-material"}). Of these, 87 proteins were differentially regulated between tmTNF^wt/wt^ and tmTNF^Δ/Δ^ mice ([Figure 6A](#F6){ref-type="fig"}). Several of the upregulated proteins, 3-mercaptopyruvate sulfurtransferase (3-MPST), hematopoietic prostaglandin D synthase (HPGDS) and apoptosis-associated speck-like protein containing a CARD (PYCARD/ASC) are neuroprotective ([@B51]; [@B10]; [@B40]; [@B71]) or related to regulation of phagocytosis ([@B67]; [@B33]). 3-MPST has previously been shown to be upregulated in activated microglia treated with a neuroprotective compound ([@B16]). tmTNF expressing microglia had an increased expression of HPGDS, which is known to be expressed in activated microglia in the core of the infarct after ischemic stroke and to enhance their differentiation into a phagocytic phenotype ([@B58]; [@B50]). PYCARD/ASC supports the function of a normal immune system ([@B33]). Among the downregulated proteins was MPO. Interestingly, upregulation of myeloperoxidase (MPO) expression is linked to pathological phagocytosis of myelin leading to demyelination in patients with multiple sclerosis ([@B57]; [@B26]). Moreover, the expression of Methyl-CpG-binding protein 2 (MECP2) ([@B17]) was downregulated in tmTNF expressing microglia. The absence of microglial MECP2 has shown to increase *Tnf* mRNA expression ([@B17]). Interestingly, tmTNF expressing microglia had downregulated expression of Histone H1.5, which promotes microglial proinflammatory functions ([@B24]), Heat shock protein 27, which is neuroprotective in ischemic brain ([@B76]) and Heat shock 70 kDa protein 1, which functions as a chaperone ([@B75]) supporting earlier studies showing solTNF to be needed for optimal control of inflammatory response ([@B68]; [@B61]; [@B18]; [@B19]). Downregulation of Human growth and transformation-dependent protein (HGTD-P), a protein which is proapoptotic in ischemia ([@B66]), and downregulation of Vimentin, which has been shown to mediate microglial activation ([@B35]), supports the beneficial function of tmTNF. Two other histones, Histone H4 and Core histone macro-H2A.1 were downregulated in tmTNF expressing microglia. String analysis of the differentially regulated proteins in microglia showed clustering of the aforementioned immune system-related proteins Histone H1.5, Heat shock protein 27, Methyl-CpG-binding protein 2, Heat shock 70 kDa protein, Core histone macro-H2A.1, Vimentin, HPGDS, and Histone H4 ([Figure 6B](#F6){ref-type="fig"}).

![Proteome analysis of primary microglia from tmTNF^wt/wt^ and tmTNF^Δ/Δ^ mice. **(A)** Differentially expressed proteins in tmTNF^wt/wt^ and tmTNF^Δ/Δ^ microglia (*n* = 4/group). **(B)** String analysis of differentially expressed proteins in tmTNF^wt/wt^ and tmTNF^Δ/Δ^ microglia. Red circle, FCERI-mediated NF-kappa B activation; blue circle, ribosomal proteins; green circle, neutrophil degranulation; turquoise circles, proteins related to phagocytosis.](fnins-13-00781-g006){#F6}

Microglia Expressing Only tmTNF Display Improved Phagocytic Properties {#S3.SS7}
----------------------------------------------------------------------

Due to the upregulated expression of phagocytosis-related proteins in microglia expressing only tmTNF, we next investigated the phagocytic properties and morphological changes 1 day after LPS stimulation in primary microglia derived from 5 to 7 days old tmTNF^Δ/Δ^ and tmTNF^wt/wt^ pups ([Figure 7A](#F7){ref-type="fig"}). Phagocytosing microglia have a neuroprotective role in clearing apoptotic cells and debris after stroke ([@B62]; [@B72]). At 1 day after LPS stimulation, the phagocytic activity of microglia derived from tmTNF^Δ/Δ^ pups was significantly increased compared to microglia derived from tmTNF^wt/wt^ pups, measured as engulfed beads per cell ([Figure 7B](#F7){ref-type="fig"}). Cell area ([Figure 7C](#F7){ref-type="fig"}), perimeter length ([Figure 7D](#F7){ref-type="fig"}), and membrane irregularity ([Figure 7E](#F7){ref-type="fig"}) increased significantly after LPS activation in both tmTNF^wt/wt^ and tmTNF^Δ/Δ^ microglia indicating both tmTNF^wt/wt^ and tmTNF^Δ/Δ^ microglia to take an amoeboid form after LPS activation. Cell morphology was, however, comparable between tmTNF^wt/wt^ and tmTNF^Δ/Δ^ microglia after LPS activation ([Figures 7A,C--E](#F7){ref-type="fig"}).

![Microglia from tmTNF^Δ/Δ^ mice have increased phagocytic activity after LPS activation. **(A)** Primary microglia cultures stained for Iba1 (red) and DAPI (blue) demonstrating phagocytosis of FluoSpheres Carboxylate-Modified Microspheres (green). Staining of tmTNF^wt/wt^ microglia (upper left), tmTNF^wt/wt^ + LPS (upper right), tmTNF^Δ/Δ^ (lower left), tmTNF^Δ/Δ^ + LPS (lower right). Scalebar = 100μm. **(B)** Engulfed beads/cell in tmTNF^wt/wt^ and tmTNF^Δ/Δ^ microglia. N(tmTNF^wt/wt^) = 426 cells/25 FOV, n(tmTNF^wt/wt^ + LPS) = 282 cells/17 FOV, n(tmTNF^Δ/Δ^) = 169 cells/20 FOV, n(tmTNF^Δ/Δ^ + LPS) = 137 cells/20 FOV. \[Two-way ANOVA: treatment ^∗∗∗^*p* \< 0.001, *F*~(1,\ 78)~ = 6.03; genotype ^\*^*p* \< 0.05, *F*~(1,\ 78)~ = 210.1; interaction ^∗∗^*p* \< 0.01 *F*~(1,\ 78)~ = 8.05\]. **(C--E)** Morphological features of microglia before and after LPS activation. **(C)** Area. \[Two-way ANOVA: treatment ^∗∗∗^*p* \< 0.001, *F*~(1,\ 78)~ = 373.3\]. **(D)** Perimeter. \[Two-way ANOVA: treatment ^∗∗∗^*p* \< 0.001, *F*~(1,\ 78)~ = 96.08\]. **(E)** Ruffling. \[Two-way ANOVA: treatment ^∗∗∗^*p* \< 0.001, *F*~(1,\ 78)~ = 132.5\]. For C-E, N(tmTNF^wt/wt^) = 426 cells/25 FOV, n(tmTNF^wt/wt^ + LPS) = 282 cells/17 FOV, n(tmTNF^Δ/Δ^) = 169 cells/20 FOV, n(tmTNF^Δ/Δ^ + LPS) = 137 cells/20 FOV. LPS, lipopolysaccharide; FOV, field of view.](fnins-13-00781-g007){#F7}

Proteomic Characterization of Neurons Derived From tmTNF^Δ/Δ^ and tmTNF^wt/wt^ Mice {#S3.SS8}
-----------------------------------------------------------------------------------

In total, 763 proteins with two or more unique peptides were quantified by label free quantification in neurons. Of them, 11 proteins were differentially expressed between tmTNF^Δ/Δ^ and tmTNF^wt/wt^ mice ([Supplementary Figure 6](#FS1){ref-type="supplementary-material"}). Calcium-activated potassium channel subunit alpha-1 (K~Ca~1.1) was upregulated in tmTNF^Δ/Δ^ mice. HGTD-P that promotes apoptosis in ischemia ([@B66]) was downregulated in neurons derived from tmTNF^Δ/Δ^ mice suggesting improved neuroprotection.

Discussion {#S4}
==========

In the present study, we found that topical administration of the selective solTNF inhibitor XPro1595 decreased infarct volumes 1 and 3 days after pMCAO. Inhibition of TNF by the non-selective solTNF and tmTNF inhibitor etanercept showed no effect. Furthermore, there was no reduction in infarct volume or improvement in functional outcome when TNF inhibitors were delivered by i.c.v. administration, even though the concentrations of the inhibitors in brain tissue were sufficient to neutralize TNF and potentially promote neuroprotection as demonstrated in previous studies using animal models of Alzheimer's disease ([@B52]).

We have previously shown that topical, but not systemic, administration of XPro1595 decreased lesion volume and improved functional outcome after moderate spinal cord injury ([@B63]). Systemic administration of XPro1595 and etanercept had no effect on the infarct volume after pMCAO ([@B11]), and systemic etanercept administration had no effect after transient focal cerebral ischemia ([@B78]), indicating that TNF inhibitors have to be administered directly to infarcted brain tissue and not by intracerebroventricular or peripheral routes. The length of treatment may also play a role in suppressing the infarct formation in the acute phase of ischemic stroke. It is known that the infarct volume correlates with functional outcome ([@B69]; [@B86]), and since TNF inhibitors are known to improve functional outcome even without reduction in infarct volume when administered systemically ([@B11]), assessment of the functional outcome would have been ideal to evaluate the neuroprotective effects of topical XPro1595 administration. Evaluation of the functional outcome was impossible, however, due to the placement of the mini-osmotic pumps in topically treated animals.

The expression of *Tnf* mRNA in central nervous system has been shown to peak 12 h after pMCAO in mice ([@B47], [@B43]), and TNF protein expression 24 h after pMCAO ([@B47], [@B43]; [@B14]). Expression of *Tnf* mRNA in the contralateral hemisphere has been shown to remain at baseline levels after pMCAO ([@B43]). In permanent focal cerebral ischemia, TNF is believed to exert its neuroprotective effects through TNFR1 ([@B81]; [@B43]). *Tnfr1* mRNA expression peaks 1--2 days after pMCAO ([@B44], [@B43]), while the protein expression can be detected from 4 to 6 h until 5 days ([@B5]; [@B44]). The expression of *Tnfr2* increases 1--10 days after pMCAO and reaches its peak 5 days after occlusion ([@B44]). The protein expression of TNFR2 can be detected 24 h after pMCAO ([@B5]). In our study, topical administration of XPro1595 tended to suppress the expression of TNF protein 1 day after pMCAO, while gene expression was significantly upregulated due to the feedback mechanism by which TNF induces its own gene expression when the amount of available protein is repressed. In addition, inhibition of both solTNF and tmTNF with etanercept downregulated TNFR1 protein levels at day 1. Together with earlier findings that TNFR1 knock-out mice develop larger infarct volumes ([@B8]; [@B23]) and neuroprotection in ischemic stroke is mediated through the TNFR1-NFκB-FLIP(L)-ERK1/2 pathway ([@B81]; [@B43]; [@B54]), downregulation of TNFR1 is likely to contribute to the lack of neuroprotection after TNF inhibition with etanercept ([@B23]; [@B43]). Given the neuroprotective effect of TNFR2 signaling in our spinal cord injury model ([@B63]) and the protective effect of this receptor in chronic, inflammatory conditions such as multiple sclerosis ([@B6]; [@B22]), we cannot exclude that TNFR2 signaling on microglia may have contributed to the protective effects observed after topical XPro1595 treatment.

TNF is primarily secreted by activated resident microglia and at later time points by infiltrating macrophages after pMCAO ([@B14]; [@B43]). In contrast to earlier studies showing that systemic inhibition of solTNF increased the number of microglia 6 and 24 h after pMCAO ([@B11]), flow cytometric analysis of the percentage of microglia and infiltrating macrophages or their CD11b and CD45 MFI values showed no difference between treatment groups. Interestingly, the number of CD45^dim^CD11b^+^ microglia was higher in sham mice treated with either TNF inhibitor when compared to saline-treated mice. In contrast to earlier studies where XPro1595 decreased glial activation in an animal model of Parkinson's disease ([@B3]), it is possible that topical administration of XPro1595 shifted the microglial phenotype without influencing the activation status of the cells. In support of this, *Cx3cr1* mRNA levels were significantly downregulated after 1 and 3 days of topical administration of XPro1595. Also, CX3CR1 deficiency has been shown to be neuroprotective in the early phase after ischemia by promoting microglial polarization to an M2-like phenotype and to decrease microglial activation and neurotoxicity by decreasing the expression of M1-like microglial phenotype that is associated with proinflammatory molecules; all of which lead to smaller infarct volumes ([@B21]; [@B80]). XPro1595 also increased the expression of *P2ry12*, a protein related to resting state microglia ([@B31]), 1 day after pMCAO when administered topically, suggesting that XPro1595 decreases microglial activation as earlier reported ([@B3]; [@B32]; [@B63]; [@B52]). Furthermore, the expression of *Trem2* was upregulated 1 and 3 days after pMCAO in mice treated topically with XPro1595. Trem2-knock out mice have altered microglial phagocytosis and larger infarct volumes after cerebral ischemia ([@B79]; [@B38]), supporting earlier studies where XPro1595 was found to promote neuroprotection by improving phagocytosis of dying neurons and cell debris in demyelinated lesions in an animal model of multiple sclerosis ([@B37]). Chemokine expression was also altered after treatment with TNF inhibitors.

In the present study, topical administration of XPro1595 increased the relative expression of *Ccl2* mRNA 3 days after pMCAO. CCL2 is necessary for hypoxia-required ischemic tolerance, and upregulation after XPro1595 treatment supports the neuroprotective properties of the selective solTNF inhibitor ([@B77]; [@B85]). *Cxcl1* mRNA, a proinflammatory granulocyte attracting chemokine expressed by monocytes and granulocytes, was upregulated in etanercept-treated but not XPro1595-treated mice 1 and 3 days after pMCAO. However, there was no difference in the CXCL1 protein levels or in granulocyte infiltration between the treatment groups, contradicting earlier findings where systemic treatment with TNF inhibitors decreased the number of infiltrating granulocytes ([@B11]) and TNF deficiency increased the number of infiltrating leukocytes 24 h after pMCAO ([@B43]).

Intracerebroventricular administration of XPro1595 or etanercept had no effect on the infarct volume nor any beneficial effect on functional outcome despite both drugs being shown to access neural tissue in therapeutically relevant concentrations. In both experimental conditions (i.c.v. versus topical administration), XPro1595 and etanercept were present in more than 1000-fold excess of TNF in the ischemic brain tissue. However, it is possible that despite the penetration of XPro1595 and etanercept, the drugs did not reach their site of action, the penumbra, within the therapeutic window, which in our pMCAO model has been shown to be 6 h ([@B15]).

Proteomic characterization of microglia derived from tmTNF^Δ/Δ^ mice revealed that several phagocytosis-related proteins were significantly upregulated compared to proteins from microglia derived from tmTNF^wt/wt^ mice. Microglia derived from tmTNF^Δ/Δ^ mice showed an upregulated expression of 3-MPST, an enzyme protecting cells from oxidative stress by producing redox regulators ([@B40]). In addition, 3-MPST regulates hydrogen sulfide production, which has been shown to promote phagocytosis ([@B20]), functions as a vasodilator supporting blood flow ([@B87]), and promotes angiogenesis ([@B64]). Among the upregulated proteins was HPGDS, which is upregulated in microglia and macrophages after ischemic stroke and is likely to promote microglia/macrophage differentiation to the phagocytic phenotype ([@B58], [@B59]; [@B50]). In addition, HPGDS inhibits production of reactive oxygen species and downregulates the expression of the pro-inflammatory cytokine IL-1β through the formation of prostaglandins ([@B25]). Microglia derived from tmTNF^Δ/Δ^ mice also had an upregulated expression of PYCARD/ASC. PYCARD/ASC deficient mice have impaired lymphocyte migration and are deficient in the number of lymphocytes and dendritic cells in secondary lymphoid organs compromising the normal immune system function ([@B33]). Upregulation of the microglial PYCARD/ASC could contribute to the maintenance of the innate immune system and the secondary lymphoid organs where tmTNF has shown to be crucial ([@B68]; [@B2]). Among the downregulated proteins in tmTNF expressing microglia was MPO, a reactive oxygen species generating enzyme known to be expressed by leukocytes and to increase in cerebral ischemia ([@B48]; [@B7]). Inhibition of MPO increases the proliferation and survival of neurons in animal models of ischemic stroke ([@B39]). In addition, HGTD-P, that mediates apoptosis in the ischemic brain when activated by hypoxia-inducible factor-1 ([@B66]), was downregulated in tmTNF expressing microglia.

In order to study whether the up- and downregulation of the phagocytosis-related proteins would affect microglial phagocytosis *in vitro*, we tested phagocytic capacity after 1 day of LPS stimulation. Primary microglia derived from tmTNF^Δ/Δ^ mice showed increased phagocytic activity that most likely can lead to increased clearing of debris thereby promoting neuronal survival in the ischemic area when solTNF is ablated. Earlier studies have demonstrated increased phagocytosis after inhibition of solTNF ([@B36]) and impaired phagocytic ability of TNFR2 deficient microglia ([@B22]). Since tmTNF preferentially binds to TNFR2, it is likely that phagocytosis is regulated through the tmTNF-TNFR2 pathway. In the present study, we also show that inhibition of solTNF by XPro1595 increased the gene expression of *Trem2*, a receptor that is known to be involved in promoting microglial phagocytosis ([@B79]), an upregulation that was likely to increase microglial phagocytosis in mice treated topically with XPro1595.

This study demonstrates that selective inhibition of solTNF is neuroprotective after pMCAO when administered topically for 1 and 3 consecutive days. Furthermore, topical administration of XPro1595 promotes a phagocytic, microglial phenotype possibly supporting a neurotrophic environment in the ischemic lesion. We suggest that topical administration of XPro1595 has potential to be clinically beneficial in treating patients with ischemic stroke.
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3-MPST

:   3-mercaptopyruvate sulfurtransferase

Arg1

:   arginase 1

CCL2

:   C-C motif chemokine ligand 2

CV

:   coefficient of variation

CXCL1

:   C-X -C motif chemokine ligand 1

CXCL10

:   C-X -C motif chemokine ligand 10

Cx3cr1

:   C-X 3-C motif chemokine receptor 1

FBS

:   fetal bovine serum

FDR

:   false discovery rate

FMO

:   fluorescence minus one

HBSS

:   Hanks' Balanced Salt Solution

HGTD-P

:   human growth and transformation-dependent protein

HPGDS

:   hematopoetic prostaglandin D synthase

HPRT1

:   hypoxanthine phosphoribosyltransferase 1

i.c.v.

:   intracerebroventricular

IL-1 β

:   interleukin-1 β

INOS

:   inducible nitric oxide synthase

LPS

:   lipopolysaccharide

MCA

:   middle cerebral artery

MECP

:   methyl-CgP-binding protein 2

MFI

:   mean fluorescent intensity

MPO

:   myeloperoxidase

PBS

:   phosphate buffered saline

pMCAO

:   permanent middle cerebral artery occlusion

P2ry12

:   P2Y purinoceptor 12

PYCARD

:   apoptosis-associated speck-like protein containing CARD

RIN

:   RNA integrity factor

RT-PCR

:   reverse transcriptase-polymerase chain reaction

s.c.

:   subcutaneously

solTNF

:   soluble tumor necrosis factor

SSC

:   side scatter

TACE

:   tumor necrosis factor alpha converting enzyme

tmTNF

:   transmembrane tumor necrosis factor

TNF

:   tumor necrosis factor

TNFR1

:   tumor necrosis factor 1

TNFR2

:   tumor necrosis factor 2

Trem2

:   triggering receptor expressed on myeloid cells-2

UPLC-MS/MS

:   [ultra-performance liquid]{.ul} chromatography-tandem mass spectrometry.
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